Data completeness
2/8 — Basic
COLY-MYCIN S (colistin sulfate) by Pfizer is clinical pharmacology colistin sulfate is a polypeptide antibiotic which penetrates into and disrupts the bacterial cell membrane. Approved for superficial bacterial infections of the external auditory canal, caused by organisms susceptible to the action of the antibiotics.
Drug data last refreshed 26m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COLY-MYCIN S (colistin sulfate) is a combination otic suspension containing colistin sulfate, neomycin sulfate, hydrocortisone acetate, and thonzonium bromide. It treats superficial bacterial infections of the external auditory canal caused by susceptible gram-positive and gram-negative organisms. The fixed combination works via polypeptide antibiotic cell membrane disruption, aminoglycoside protein synthesis inhibition, and corticosteroid anti-inflammatory action.
Launch
Pre-launch asset under Pfizer sponsorship entering a crowded but stable otologic antibiotic market; brand team will focus on differentiation against established competitors.
Mechanism of Action
CLINICAL PHARMACOLOGY Colistin sulfate is a polypeptide antibiotic which penetrates into and disrupts the bacterial cell membrane. Neomycin sulfate is an aminoglycoside antibiotic which inhibits protein synthesis, disrupting the normal cycle of ribosomal function. Hydrocortisone acetate is a…
Worked on COLY-MYCIN S at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.